UBIOProShares UltraPro Nasdaq Biotechnology
UBIO Fund Description
UBIO provides 3x daily exposure to a market-cap-weighted index of biotechnology and pharmaceutical companies listed on NASDAQ.
UBIO Factset Analytics Insight
UBIO offers 3x the daily gains and losses of its index, which is tracked in unlevered form by the hugely popular IBB, from iShares. That means it inherits all of IBB’s quirks—most notably its NASDAQ-only listing requirement, and its inclusion of a good number of pharmaceutical companies outside of the pure-play biotech space. UBIO gains its leverage through a mix of equity and swap agreements, and resets its exposure daily. Like all geared funds that rebalance daily, UBIO is meant for short-term trading, since compounding effects over the long term could create vast differences from expected returns relative to the index—for good or for ill. Note that 2x exposure to the same index can be had from sibling fund BIB. UBIO competes with Direxion’s LABU, which tracks a triple-levered S&P index.
UBIO Charts And Performance
UBIO Factset Analytics Block Liquidity
This measurement shows how easy it is to trade a $1 million USD block of UBIO. UBIO is rated a N/A out of 5.